2024-05-13T11:04:23-04:00 2023-06-30 851572996 MORIARTY & ASSOCIATES PC 144 GOULD ST STE 205 NEEDHAM MA 02494 990 2022-07-01 843043384 MISSION CURE INC MISS CO MEGAN GOLDEN 245 W 107TH ST STE NEW YORK NY 10025 MEGAN GOLDEN CEO 4013752873 2024-05-10 true MEGAN GOLDEN MICHAEL P MORIARTY CPA P00574082 6178522214 2024-05-13 0 00 AAL1 IAL1 2022 2023-04-26 12:10:37Z 561098 false X MISSION-CURE.ORG X 2019 DE SEE SCHEDULE O 6 6 6 10 0 0 724152 554907 0 6191 -18000 -25021 706152 536077 50000 0 0 326021 305857 0 38257 75920 121951 451941 427808 254211 108269 940800 1037087 15471 3489 925329 1033598 X SEE SCHEDULE O false false 339645 THE ORGANIZATIONS MAJOR PROGRAMS CONSIST OF DEVELOPING THERAPIES, ENGAGING COMMUNITIES AND IMPROVING CARE (SEE SCHEDULE O - PART III RESPONSES). 339645 true true false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false false false false false false true 8 0 true 6 true false false false false false false false false false false false false false false X 6 6 false false true false false false false true true false false true true true true true true true true false CA NY X MEGAN GOLDEN 4013752873 245 W 107TH ST APT 11B NEW YORK NY 10025 LOLA RAHIB PHD VP OF TRANSALATIONAL RESEARCH 40.00 0.00 X 129808 0 5532 MEGAN GOLDEN PRESIDENT AND CEO 40.00 0.00 X X 82500 0 0 JAMES MEDSKER DIRECTOR 2.00 0.00 X 0 0 0 SAM SHRAUGER DIRECTOR 2.00 0.00 X 0 0 0 LINDA MARTIN BOARD CHAIRPERSON 8.00 0.00 X X 0 0 0 MICHAEL LEVITAN TREASURER 2.00 0.00 X X 0 0 0 BRUCE BLOOM SECRETARY 2.00 0.00 X X 0 0 0 212308 0 5532 1 false false false 224997 329910 24600 554907 6191 6191 224997 25021 -25021 -25021 536077 6191 0 -25021 X 82500 65020 15780 1700 188062 184219 1545 2298 13553 13418 110 25 21742 20029 1392 321 17940 17940 63708 25049 5358 33301 5901 5292 609 810 121 689 4418 462 3356 600 17209 17209 6545 6470 75 1624 1624 BANK CHARGES 216 216 DUES & SUBSCRIPTIONS 2642 2356 286 PAYROLL PROCESSING 938 926 12 427808 339645 49906 38257 906061 1035909 34000 739 1178 940800 1037087 15471 3489 15471 3489 X 716329 961173 209000 72425 925329 1033598 940800 1037087 108269 0 X true X false false false X 950164 724152 554907 2229223 950164 724152 554907 2229223 169932 2059291 2229223 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED GALA 224997 224997 25021 224997 224997 25021 25021 -25021 Organizational document changes Part VI line 4 THE ORGANIZATION MODIFIED IS BYLAWS IN JUNE 2023 TO CREATE TWO CLASSES OF BOARD MEMBERS WITH STAGGERED 2-YEAR TERMS. Form 990 governing body review Part VI line 11 THE ORGANIZATION PROVIDES A DRAFT COPY OF FORM 990 FOR THE BOARD TO REVIEW PRIOR TO FILING. Conflict of interest policy compliance Part VI line 12c BOARD MEMBERS AND KEY EMPLOYEES ANNUALLY COMPLETE CONFLICT OF INTEREST DISCLOSURE FORMS. AT EACH BOARD MEETING BOARD MEMBERS AND THE CEO ARE ASKED TO DISCLOSE ANY NEW CONFLICTS OF INTEREST. CEO executive director top management comp Part VI line 15a THE ORGANIZATION USES THE DEPARTMENT OF LABOR STATISTICS AND SALARY GUIDE TO OBTAIN COMPARABLE DATA WHEN ESTABLISHING COMPENSATION FOR THE CEO. FURTHERMORE, THE ORGANIZATION PERIODICALLY REVIEW THE COMPENSATION ARRANGEMENTS AND BENEFITS TO ENSURE THAT THEY ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION AND THE RESULT OF ARMS LENGTH BARGAINING. Other officer or key employee compensation Part VI line 15b THE ORGANIZATION USES THE DEPARTMENT OF LABOR STATISTICS AND SALARY GUIDE TO OBTAIN COMPARABLE DATA ON ALL POSITIONS. FURTHERMORE, THE ORGANIZATION PERIODICALLY REVIEWS COMPENSATION ARRANGEMENTS AND BENEFITS TO ENSURE THAT THEY ARE REASONABLE, BASED ON COMPETENT SURVEY INFOMRATION AND THE RESULT OF ARMS LENGTH BARGAINING. Governing documents etc available to public Part VI line 19 GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, THE FINANCIAL STATEMENTS, AND OTHER DOCUMENTS, SUCH AS THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. List of other fees for services expenses Part IX line 11g OTHER CONSULTANTS AND OUTSIDE SERVICES:FUNDRAISING - $33,301STRATEGY & PROGRAMS - $25,049STAFFING & ADMINISTRATION - $5,358 Part III response or note to any other line in Part III DEVELOPING THERAPIES: HELPED LAUNCH AND COMPLETE ENROLLMENT FOR PILOT CLINICAL TRIAL OF CHRONIC PANCREATITIS THERAPY WITH GEORGETOWN UNIVERSITY; SUPPORTED JOHNS HOPKINS PANCREATITIS PAIN RESEARCH IN TREATING 20+ PATIENTS; LAUNCHED STUDY FOR PRECISION MEDICINE CHRONIC PANCREATITIS CLINICAL TRIAL AT CEDARS-SINAI; LED MULTI-STAKEHOLDER STUDY TO IDENTIFY OUTCOMES TO BE USED IN PANCREATITIS CLINICAL TRIALS; ADVOCATED WITH LIFE SCIENCES COMPANIES TO PURSUE THERAPIES FOR PANCREATITIS & PROVIDED INFORMATION TO SUPPORT DRUG DEVELOPMENT.ENGAGING COMMUNITIES: ENGAGED OVER 71,500 PATIENTS,CAREGIVERS,CLINICIANS AND SCIENTISTS WITH OUR WEBSITE. EDUCATIONAL VIDEOS RECEIVED 47,750+ VIEWS FOR MORE THAN 6,100 HOURS; LAUNCHED A REDISGNED MORE ACCESSIBLE WEBSITE; PROVIDED NEW EDUCATIONAL INFORMATION. IMPROVING CARE: COLLABORATED WITH JOHNS HOPKINS UNIVERSITY TO OPERATE PANCREATITIS PAIN RESEARCH PROGRAM; WITH AVOMD, PUT PRACTICAL GUIDELINES FOR TREATING EXOCRINE PANCREATIC INSUFFICIENCY ON AN APP AND WEBSITE TO IMPROVE TREATMENT; PRESENTED TO LEADING CLINICIANS ON BEST PRACTICES FOR INTERDISCIPLINARY PANCREATITIS CARE.